Module 1 (EU) — Administrative & Summary of Product Characteristics — GLPI-103

Region-specific administrative content and the Summary of Product Characteristics (SmPC) per the QRD template. Clinical figures trace to CSR-301 (outputs/). [MOCK] administrative identifiers.

Change History

1.0 Cover Letter & Application Form [MOCK]

Virtual Biopharma Inc. submits this Marketing Authorisation Application for GLPI-103 under the centralised procedure. Enclosed: EU application form, proposed SmPC/Annex I, Annex II, labelling, Package Leaflet (with user-consultation/readability test summary), and Modules 2–5. The EU-RMP (RMP-EU) is included.

Summary of Product Characteristics (SmPC)

1. Name of the medicinal product: GLPI-103 solution for injection; GLPI-103 tablets.

2. Qualitative and quantitative composition: Each presentation contains GLPI-103 as the active substance (IV vial; oral tablet with permeation enhancer). For the full list of excipients, see section 6.1 and Module 3.

3. Pharmaceutical form: Solution for injection (intravenous); tablet (oral).

4. Clinical particulars

• 4.1 Therapeutic indications: GLPI-103 is indicated in adults for the treatment of type 2 diabetes mellitus inadequately controlled on metformin, as add-on therapy, to improve glycaemic control.
• 4.2 Posology and method of administration: IV once weekly, titrated 1→2→4 mg (maintenance 4 mg). Oral once daily, titrated 2→4→8 mg (maintenance 8 mg). Titrate to manage gastrointestinal tolerability. Special populations: no dose adjustment anticipated by age/sex; not recommended in severe renal/hepatic impairment (not studied).
• 4.3 Contraindications: Hypersensitivity to the active substance or excipients; personal or family history of medullary thyroid carcinoma or MEN 2.
• 4.4 Special warnings and precautions for use: Acute pancreatitis (discontinue if suspected; do not re-initiate if confirmed); gastrointestinal effects (titration; risk of dehydration); hypoglycaemia in combination with sulfonylurea/insulin (consider reducing the secretagogue/insulin dose); thyroid C-cell monitoring; cardiovascular/heart-rate monitoring (mechanism-related).
• 4.5 Interactions: Delayed gastric emptying may affect absorption of concomitant oral medicinal products; low pharmacokinetic-interaction potential otherwise.
• 4.6 Fertility, pregnancy and lactation: Limited data; not recommended during pregnancy/breast-feeding unless clearly necessary; WOCBP should use effective contraception.
• 4.7 Effects on ability to drive and use machines: Negligible, except in the context of hypoglycaemia.
• 4.8 Undesirable effects: Very common: nausea, vomiting, diarrhoea, decreased appetite. In GLPI103-301 (N=900), nausea occurred in 32.3% (GLPI-103 IV) versus 21.4% (comparator), a non-significant difference; injection-site reactions were more frequent with the IV formulation; hypoglycaemia was infrequent (CSR-301 §12; M2.7.4).
• 4.9 Overdose: Manage symptomatically; gastrointestinal effects expected.

5. Pharmacological properties

• 5.1 Pharmacodynamic properties: ATC code (to be assigned); GLP-1/APJ dual receptor agonist. In the pivotal study, GLPI-103 was superior to oral semaglutide on HbA1c at Week 52 (IV −0.68%, oral −0.34%; both p<0.001), with greater weight reduction and higher responder rates (M2.7.3).
• 5.2 Pharmacokinetic properties: Long half-life (once-weekly IV); oral bioavailability via permeation enhancer; proteolytic catabolism; low immunogenicity (M2.7.2).
• 5.3 Preclinical safety data: Class-consistent; reversible exaggerated-pharmacology effects; thyroid C-cell monitoring; negative genotoxicity (M2.4).

6. Pharmaceutical particulars: excipients, incompatibilities, shelf life, storage, container, and disposal per Module 3.

Annex II / Annex III: conditions of the marketing authorisation (including the RMP-EU and any additional risk-minimisation measures), labelling, and Package Leaflet.